Boothbay Fund Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-15,900
Closed -$2.48M 1620
2024
Q2
$2.48M Sell
15,900
-29,050
-65% -$4.37M 0.06% 434
2024
Q1
$6.09M Buy
+44,950
New +$5.95M 0.12% 175
2023
Q3
Sell
-172,650
Closed -$24.7M 1727
2023
Q2
$24.7M Buy
172,650
+119,150
+223% +$17.5M 0.54% 18
2023
Q1
$7.43M Buy
+53,500
New +$7.2M 0.15% 134
2021
Q4
Sell
-5,050
Closed -$607K 1862
2021
Q3
$607K Buy
+5,050
New +$588K 0.02% 999
2021
Q2
Sell
-182
Closed -$1.81M 1840
2021
Q1
$1.81M Hold
182
0.07% 355
2020
Q4
$1.82M Buy
+182
New +$19.3K 0.07% 292

Other funds holding AZN

Boothbay Fund Management's AZN Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in AstraZeneca (AZN) in Q1 2026: 3,867 shares worth $763K. The stake represents 0.01% of the portfolio and ranks #1099 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in AZN as recently as Q3 2025.

Boothbay Fund Management first reported a position in AZN in Q3 2019 and has held it in 17 quarters since. The position peaked at $10.2M in Q1 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Boothbay Fund Management held 3,867 shares of AstraZeneca worth $763K as of Q1 2026.
  • AstraZeneca was a new Boothbay Fund Management position in Q1 2026.
  • AstraZeneca made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1099 holding.
  • Boothbay Fund Management first reported a position in AstraZeneca in Q3 2019 and has held it in 17 quarters since.
  • Boothbay Fund Management's AstraZeneca position peaked at $10.2M in Q1 2021.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.